ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
21.303,82
1,25%
S&P 500
6.086,37
0,61%
Dow Jones
44.156,73
0,30%
Euro vs US Dollar
1,04099
0,02%
Bitcoin
103.310,00
-0,32%
Pepperstone
Advertisement
Registration Strip Icon for discussion Registrieren Sie sich, um in unseren aktiven Foren mit gleichgesinnten Anlegern zu diskutieren.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ

  6. Denali Therapeutics Inc (DNLI) Börsenkurse

Denali Therapeutics Inc

Denali Therapeutics Inc (DNLI)

NASDAQ
23,31
0,27
(1,17%)
Beim Schlusskurs: 23 Januar 10:00PM
Verzögert um 15 Minuten
23,31
0,00
( 0,00% )
Nach Börsenschluss: 12:00AM
Verzögert um 15 Minuten

Ihr Hub für Echtzeit-Streaming-Zitate, Ideen und Live-Diskussionen

Premium

Wichtige Statistiken und Details

Current Price
23,31
Gebot
19,32
Fragen
24,50
Volumen
1.013.494
22,72 Tagesbereich 23,69
14,56 52-Wochen-Bereich 33,33
Marktkapitalisierung
3,355B
Handelsende
23,04
Handelsbeginn
23,04
Letzte Trade
14642
@
23.31
(formt)
Letzter Handelszeitpunkt
22:41:30
Finanzvolumen
US$ 23.552.035
VWAP
23,2385
Durchschnittliches Volumen (3 Mio.)
949.016
Ausgegebene Aktien
143.921.624
Dividendenrendite
-
Kurs-Gewinn-Verhältnis
-23,10
Gewinn pro Aktie (EPS)
-1,01
Erlöse
330,53M
Nettogewinn
-145,22M

Über Denali Therapeutics Inc

Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegeneration disease. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates ... Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegeneration disease. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, DNL747, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others. Mehr anzeigen

Sektor
Biological Pds,ex Diagnstics
Branche
Biological Pds,ex Diagnstics
Website
www.denalitherapeutics.com
Hauptsitz
Wilmington, Delaware, USA
Gegründet
-
Denali Therapeutics Inc is listed in the Biological Pds,ex Diagnstics sector of the NASDAQ with ticker DNLI. The last closing price for Denali Therapeutics was US$23,04. Over the last year, Denali Therapeutics shares have traded in a share price range of US$ 14,56 to US$ 33,33.

Denali Therapeutics currently has 143.921.624 shares in issue. The market capitalisation of Denali Therapeutics is US$3,32 billion. Denali Therapeutics has a price to earnings ratio (PE ratio) of -23.10.

DNLI Neueste Nachrichten

Weitere Nachrichten

Form 8-K - Current report

13 Januar 2025
Edgar (US Regulatory)

Denali Therapeutics Announces Key Anticipated 2025 Milestones and Priorities to Further Advance Its Therapeutics Portfolio for Neurodegeneration and Lysosomal Storage Diseases

FDA Breakthrough Therapy Designation received for tividenofusp alfa for Hunter syndrome (MPS II); on track to submit biologics license application (BLA) in early 2025Preparing for commercial...

13 Januar 2025
GlobeNewswire Inc.

Form 4 - Statement of changes in beneficial ownership of securities

09 Januar 2025
Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities

09 Januar 2025
Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities

09 Januar 2025
Edgar (US Regulatory)

Denali Therapeutics Announces U.S. FDA Breakthrough Therapy Designation Granted to Tividenofusp Alfa for the Treatment of Hunter Syndrome (MPS II)

SOUTH SAN FRANCISCO, Calif., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI), today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough...

08 Januar 2025
GlobeNewswire Inc.

Form 144 - Report of proposed sale of securities

08 Januar 2025
Edgar (US Regulatory)

Form 144 - Report of proposed sale of securities

08 Januar 2025
Edgar (US Regulatory)

Form 144 - Report of proposed sale of securities

08 Januar 2025
Edgar (US Regulatory)

Form 144 - Report of proposed sale of securities

08 Januar 2025
Edgar (US Regulatory)
Zeitraum †ÄnderungÄnderung %HandelsbeginnHochNiedrigDurchsch. VolumenVWAP
13.6718.686354378819.6423.3319.45121483821.93780943CS
42.612.554321583820.7123.3318.52101924420.77904751CS
12-3.91-14.364437913327.2233.3318.5294901623.69017067CS
261.697.8168362627221.6233.3318.5292088325.02882112CS
526.0234.817813765217.2933.3314.56104580121.94479695CS
156-8.71-27.201748906932.0239.4314.5683132624.7239704CS
2601.135.0946798917922.1893.9412.3974053831.99265275CS

DNLI - Frequently Asked Questions (FAQ)

What is the current Denali Therapeutics share price?
The current share price of Denali Therapeutics is US$ 23,31
How many Denali Therapeutics shares are in issue?
Denali Therapeutics has 143.921.624 shares in issue
What is the market cap of Denali Therapeutics?
The market capitalisation of Denali Therapeutics is USD 3,32B
What is the 1 year trading range for Denali Therapeutics share price?
Denali Therapeutics has traded in the range of US$ 14,56 to US$ 33,33 during the past year
What is the PE ratio of Denali Therapeutics?
The price to earnings ratio of Denali Therapeutics is -23,1
What is the cash to sales ratio of Denali Therapeutics?
The cash to sales ratio of Denali Therapeutics is 10,15
What is the reporting currency for Denali Therapeutics?
Denali Therapeutics reports financial results in USD
What is the latest annual turnover for Denali Therapeutics?
The latest annual turnover of Denali Therapeutics is USD 330,53M
What is the latest annual profit for Denali Therapeutics?
The latest annual profit of Denali Therapeutics is USD -145,22M
What is the registered address of Denali Therapeutics?
The registered address for Denali Therapeutics is 1209 ORANGE STREET, WILMINGTON, DELAWARE, 19801
What is the Denali Therapeutics website address?
The website address for Denali Therapeutics is www.denalitherapeutics.com
Which industry sector does Denali Therapeutics operate in?
Denali Therapeutics operates in the BIOLOGICAL PDS,EX DIAGNSTICS sector

Beweger

Alle Anzeigen
  • Volumen
  • % Tops
  • % Flops
SymbolPreisVol.
AALAmerican Airlines Group Inc
US$ 0,00
(0,00%)
0
AAGRAfrican Agriculture Holdings Inc
US$ 0,00
(0,00%)
0
AADRAdvisorShares Dorsey Wright ADR ETF
US$ 0,00
(0,00%)
0
AADIAadi Bioscience Inc
US$ 0,00
(0,00%)
0
AACGATA Creativity Global
US$ 0,00
(0,00%)
0
LAKELakeland Industries Inc
US$ 22,00
(-13,73%)
23,99k
ASTSAST SpaceMobile Inc
US$ 19,67
(-12,54%)
3,06M
SOBRSOBR Safe Inc
US$ 0,92
(-11,54%)
318,78k
EAElectronic Arts Inc
US$ 126,20
(-11,35%)
1,04M
ERNAEterna Therapeutics Inc
US$ 0,5725
(-9,86%)
491,99k
TNXPTonix Pharmaceuticals Holding Corporation
US$ 0,3101
(-2,79%)
26,57M
KOPNKopin Corporation
US$ 1,88
(27,89%)
14,65M
RIMEAlgorhythm Holdings Inc
US$ 0,0349
(5,12%)
11M
ACONAclarion Inc
US$ 0,041
(-1,20%)
8,21M
BLBXBlackBoxStocks Inc
US$ 5,281
(-4,33%)
6,45M

Foren

Foren anzeigen
Keine Diskussionen Gefunden.
Neuen Thread Erstellen

Kürzlich von Ihnen besucht

NASDAQ
DNLI
Denali Therapeutics
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2025 ADVFN PLC - Alle Rechte vorbehalten